Develops eye injections for wet age-related macular degeneration.
Sep 2025Revenue $1.41M/yrExpenses $68.5M/yr
No trendCash runway ≈ 2 months from Jun 2026
Figures by year
When will Outlook Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Sep 2025, revenue was $1.41M and expenses $68.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $1.41M | $68.5M | −$67.1M |
| Sep 2019 | $8.15M | $44.4M | −$36.3M |
| Sep 2018 | $3.09M | $32.7M | −$29.6M |
| Sep 2017 | $3.81M | $39.7M | −$35.9M |
| Sep 2016 | $2.98M | $54.3M | −$51.3M |
| Sep 2015 | $5.22M | $51.8M | −$46.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.